calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) (CAS 344423-98-9) — formula C66H68CaF2N4O10, molecular weight 1155.3; category organic chemicals.
| CAS Number | 344423-98-9 |
|---|---|
| Molecular Formula | C66H68CaF2N4O10 |
| Molecular Weight | 1155.3 |
| Applications | Uses: Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 31300, Use (kg) in France (2004): 7924, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.012, Consumption (g per capita) in the USA (2002): 0.11, Consumption (g per capita) in France (2004): 0.13, Excretion rate: 0.46, Calculated removal (%): 97.3, May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and, or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels. |
| Category | Organic Chemicals |
Documented applications: Uses: Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 31300, Use (kg) in France (2004): 7924, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.012, Consumption (g per capita) in the USA (2002): 0.11, Consumption (g per capita) in France (2004): 0.13, Excretion rate: 0.46, Calculated removal (%): 97.3, May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and, or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels..
calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) is a carbon-based organic compound with CAS registry number 344423-98-9 and molecular formula C66H68CaF2N4O10 (molecular weight 1155.3), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 344423-98-9
Its molecular formula C66H68CaF2N4O10 comprises 66 C, 68 H, 1 Ca, 2 F, 4 N, 10 O atoms.
Also known as: calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) · 阿托伐他汀钙 结晶型
Category: organic chemicals
The CAS registry number of calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) is 344423-98-9.
Molecular formula C66H68CaF2N4O10, molecular weight 1155.3.
It is also registered under: calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3), 阿托伐他汀钙 结晶型.
Recorded applications: Uses: Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 31300, Use (kg) in France (2004): 7924, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.012, Consumption (g per capita) in the USA (2002): 0.11, Consumption (g per capita) in France (2004): 0.13, Excretion rate: 0.46, Calculated removal (%): 97.3, May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and, or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels..
Category: Organic Chemicals.
Independent reference data for calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) (CAS 344423-98-9), compiled from public chemistry databases.
| CAS 号 | 344423-98-9 |
|---|---|
| PubChem CID | 60822 |
| 分子式 | C66H68CaF2N4O10 |
| IUPAC 名称 | calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate) |
| UNII（FDA） | C0GEJ5QCSO |
| Molecular Weight | 1155.3 |
|---|---|
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 22 |
| Exact Mass | 1154.4529416 |
| Monoisotopic Mass | 1154.4529416 |
| Topological Polar Surface Area | 229 |
| Heavy Atom Count | 83 |
ATORVASTATIN CALCIUM; 134523-03-8; Tahor; Atorvastatin calcium anhydrous; CI-981; Liprimar; C0GEJ5QCSO; DTXSID6044303; Atorvastatin calcium (anhydrous); NSC-758617; DTXCID4024303; CHEBI:50686; Atorvastatin calcium salt anhydrous; Dengue Kill; RefChem:916455; Atorvastatin, Calcium salt
| GHS 通报统计 | 2% (3 / 153) |
|---|
| GHS 通报统计 | 2% (3 / 153) |
|---|---|
| 已通报的危害声明 | H315 (37.3%), H319 (38.6%), H335 (37.3%), H361 (37.3%), H362 (36.6%), H373 (36.6%), H402 (19%), H411 (35.9%) |
阿托伐他汀钙 结晶型 · CAS 344423-98-9 · C66H68CaF2N4O10. UNII C0GEJ5QCSO.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 阿托伐他汀钙 结晶型